Aravive, Inc. (ARAV): Price and Financial Metrics


Aravive, Inc. (ARAV): $1.13

0.04 (+3.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARAV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARAV Stock Summary

  • With a market capitalization of $39,430,178, Aravive Inc has a greater market value than only 7.18% of US stocks.
  • Revenue growth over the past 12 months for Aravive Inc comes in at 104.38%, a number that bests 92.25% of the US stocks we're tracking.
  • Aravive Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -84.08%, greater than the shareholder yield of only 4.82% of stocks in our set.
  • Stocks that are quantitatively similar to ARAV, based on their financial statements, market capitalization, and price volatility, are AGTC, SYBX, ALT, VBLT, and CBIO.
  • ARAV's SEC filings can be seen here. And to visit Aravive Inc's official web site, go to aravive.com.

ARAV Valuation Summary

  • ARAV's price/earnings ratio is -3; this is 108.22% lower than that of the median Healthcare stock.
  • ARAV's price/sales ratio has moved NA NA over the prior 91 months.
  • Over the past 91 months, ARAV's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ARAV.

Stock Date P/S P/B P/E EV/EBIT
ARAV 2021-08-31 9.2 1.4 -3.0 -0.6
ARAV 2021-08-30 8.7 1.3 -2.8 -0.5
ARAV 2021-08-27 8.7 1.3 -2.9 -0.5
ARAV 2021-08-26 8.7 1.3 -2.8 -0.5
ARAV 2021-08-25 8.6 1.3 -2.8 -0.5
ARAV 2021-08-24 8.6 1.3 -2.8 -0.5

ARAV Growth Metrics

    The year over year cash and equivalents growth rate now stands at 28.49%.
  • Its 5 year net cashflow from operations growth rate is now at 71.05%.
  • The 2 year net cashflow from operations growth rate now stands at 77.51%.
Over the past 15 months, ARAV's revenue has gone up $12,142,000.

The table below shows ARAV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 12.142 -19.61 -30.241
2021-06-30 9.73 -17.244 -29.815
2021-03-31 5.941 -17.726 -27.751
2020-12-31 5.685 -12.169 -30.543
2020-09-30 0 -21.465 -30.825
2020-06-30 0 -18.569 -26.307

ARAV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARAV has a Quality Grade of C, ranking ahead of 49.15% of graded US stocks.
  • ARAV's asset turnover comes in at 0.129 -- ranking 240th of 680 Pharmaceutical Products stocks.
  • ASLN, BPTH, and XBIO are the stocks whose asset turnover ratios are most correlated with ARAV.

The table below shows ARAV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.129 1 -5.812
2021-03-31 0.083 1 -3.701
2020-12-31 0.084 1 -3.246
2020-09-30 0.000 NA -2.303
2020-06-30 0.000 NA -1.625
2020-03-31 0.043 1 -1.306

ARAV Price Target

For more insight on analysts targets of ARAV, see our ARAV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.00 Average Broker Recommendation 1.3 (Strong Buy)

ARAV Stock Price Chart Interactive Chart >

Price chart for ARAV

ARAV Price/Volume Stats

Current price $1.13 52-week high $6.94
Prev. close $1.09 52-week low $1.02
Day low $1.07 Volume 43,200
Day high $1.15 Avg. volume 65,708
50-day MA $1.55 Dividend yield N/A
200-day MA $2.71 Market Cap 32.57M

Aravive, Inc. (ARAV) Company Bio


Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.


ARAV Latest News Stream


Event/Time News Detail
Loading, please wait...

ARAV Latest Social Stream


Loading social stream, please wait...

View Full ARAV Social Stream

Latest ARAV News From Around the Web

Below are the latest news stories about Aravive Inc that investors may wish to consider to help them evaluate ARAV as an investment opportunity.

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 8.74% and 6.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Aravive (ARAV) Upgraded to Buy: Here's Why

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | February 10, 2022

Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Yahoo | February 10, 2022

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Preliminary top line data anticipated throughout 2022HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has dosed the first patient in the Phase 2 portion of the Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC). “Safety and preliminary activity data from the Phase 1b study of batiraxcept in combinat

Yahoo | January 31, 2022

Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors

HOUSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that the company’s Chairman, Fred Eshelman, Pharm.D., through Eshelman Ventures, LLC, agreed to purchase a pre-funded warrant to purchase 4,545,455 shares of the company’s common stock at a price of $2.20 per share, which was the consolidated closing bid price of the company’s common stock on The Nasdaq Global

Yahoo | January 3, 2022

Read More 'ARAV' Stories Here

ARAV Price Returns

1-mo -23.13%
3-mo -47.93%
6-mo -66.67%
1-year -77.71%
3-year -81.74%
5-year -98.78%
YTD -48.40%
2021 -61.17%
2020 -58.74%
2019 288.35%
2018 -73.33%
2017 -85.23%

Continue Researching ARAV

Want to see what other sources are saying about Aravive Inc's financials and stock price? Try the links below:

Aravive Inc (ARAV) Stock Price | Nasdaq
Aravive Inc (ARAV) Stock Quote, History and News - Yahoo Finance
Aravive Inc (ARAV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0667 seconds.